| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IGHG2 |
| Uniprot No | P01859 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 99-326aa |
| 氨基酸序列 | ERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHE DPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEY KCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLV KGFYPSDISVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQ GNVFSCSVMHEALHNHYTQKSLSLSPGK |
| 预测分子量 | 26 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IGHG2重组蛋白的3篇参考文献的示例(注：以下文献为虚拟示例，实际研究中需根据真实文献调整)：
---
1. **文献名称**: *"High-yield production of recombinant human IGHG2 in CHO cells: Structural and functional analysis"*
**作者**: Müller, A., et al.
**摘要**: 本研究报道了在CHO细胞中高效表达重组人IGHG2的方法，优化了培养条件以提升产量。通过质谱和圆二色光谱分析，验证了重组蛋白的正确折叠和糖基化模式，并证明其与Fcγ受体结合活性与天然蛋白相似。
---
2. **文献名称**: *"IGHG2-specific glycosylation impacts antibody-dependent cellular cytotoxicity in cancer therapy"*
**作者**: Sato, K., & Yamamoto, T.
**摘要**: 文章探讨了重组IGHG2的糖基化修饰对抗体依赖性细胞毒性(ADCC)的影响。通过工程化改造糖链结构，显著增强了IGHG2在靶向肿瘤细胞时的效应功能，为抗体药物设计提供了新策略。
---
3. **文献名称**: *"Comparative study of IgG subclasses: IGHG2 exhibits unique stability under acidic conditions"*
**作者**: Chen, L., et al.
**摘要**: 研究比较了IgG各亚类(包括IGHG2)的理化性质，发现重组IGHG2在低pH环境下具有更高的稳定性，提示其在药物制剂开发中的潜在优势。实验通过差示扫描量热法(DSC)验证了其热稳定性。
---
**注意事项**：
- 上述文献为示例，实际引用时需通过PubMed、Web of Science等平台检索真实文献。
- 关键词建议：`IGHG2 recombinant production`、`IgG subclass functional studies`、`antibody engineering`。
- 若研究聚焦于疾病或治疗应用，可补充关键词如`therapeutic antibodies`或`disease-specific IgG2`。
**Background of Recombinant IGHG2 Protein**
The recombinant IGHG2 protein is a engineered form of the immunoglobulin gamma heavy chain constant region 2 (IGHG2), a critical component of human IgG2 antibodies. IgG2 is one of four IgG subclasses (IgG1-4) that play distinct roles in adaptive immunity. Unlike IgG1 and IgG3. which strongly engage effector functions like antibody-dependent cellular cytotoxicity (ADCC) and complement activation, IgG2 exhibits limited effector activity but shows high efficacy in neutralizing pathogens with polysaccharide-rich surfaces, such as encapsulated bacteria. This subclass is particularly important in responses to bacterial infections and certain vaccines.
Recombinant IGHG2 is produced using biotechnological methods, typically via expression systems like mammalian cells (e.g., CHO or HEK293), which ensure proper folding and post-translational modifications, including glycosylation. The protein retains the structural and functional properties of the native IgG2 heavy chain constant region, enabling its use in studying antibody structure-function relationships, immune regulation, and therapeutic development.
In biomedical research, recombinant IGHG2 serves as a tool for designing therapeutic antibodies where reduced inflammatory responses are desirable, such as in autoimmune diseases or chronic infections. It also aids in engineering bispecific antibodies or antibody-drug conjugates (ADCs) to optimize pharmacokinetics and target specificity. Additionally, it is utilized in diagnostic assays to detect IgG2-specific immune responses or to standardize immunological tests.
The development of recombinant IGHG2 underscores advancements in protein engineering and immunotherapy, offering tailored solutions for precision medicine while minimizing off-target effects. Its study continues to enhance understanding of IgG subclass-specific immunity and therapeutic potential.
×
